Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing natural killer cells NKX019

A preparation of off-the-shelf (OTS), allogeneic and ex vivo expanded natural killer cells (NKs) that are engineered to express membrane-bound IL-15 (mbIL15) and a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 that is coupled to the co-stimulatory domain of OX40 (CD134), and to the zeta chain of the TCR/CD3 complex (CD3-zeta; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration of allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing NK cells NKX019, these cells specifically target and bind to tumor cells expressing CD19. This induces secretion of pro-inflammatory cytokines and results in the lysis of CD19-expressing tumor cells. IL-15 is a pro-survival cytokine that potentiates the immune response against tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
Synonym:allogeneic anti-CD-19 CAR NK cells NKX019
allogeneic anti-CD-19 CAR-NKs NKX019
allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing NK cells NKX019
allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing NKs NKX019
Code name:NKX 019
NKX-019
NKX019
Search NCI's Drug Dictionary